Reneuron (RENE.L) is a stem cell research company whose focus is on therapies targeting areas of poorly met medical need, including peripheral arterial disease, stroke, and retinal diseases. RENE is currently testing the effects of neural stem cells on spines for neuroregeneration, and is testing the use of fetal stem cells on stroke patients.
A UK company, used as a scientific comparable due to status of trials and disease state.
January 19, 2021
RegMed Investors’ (RMi) closing bell: rebound follows decline and a holiday
January 19, 2021
RegMed Investors’ (RMi) pre-open: expected rebound but, questionable indicators
January 15, 2021
RegMed Investors’ (RMi) closing bell: momentum shifts into reverse
January 15, 2021
RegMed Investors’ (RMi) pre-open: when you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started
January 14, 2021
RegMed Investors’ (RMi) closing bell: the sector gains as markets finish lower
January 13, 2021
RegMed Investors’ (RMi) closing bell: political processes and fiscal aid timing deflates expectation
January 13, 2021
RegMed Investors’ (RMi) pre-open: what’s a preferred narrative?
January 12, 2021
RegMed Investors’ (RMi) closing bell: in which wave are we investing?
January 11, 2021
RegMed Investors’ (RMi) closing bell: Washington tension drains sentiment
January 8, 2021
RegMed Investors’ (RMi) closing bell: the finger came out of the dike of record highs
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.